Projects per year
Personal profile
Biography
Dr Ing Soo Tiong is a clinical haematologist consulting from Eastern Haematology Oncology Group.
He graduated from the University of Otago and completed his Basic Physician Training in Dunedin, New Zealand. He joined Alfred Hospital (2016) as the Leukaemia Fellow, awarded the HSANZ New Investigator Scholarship for 2017, and completed Haematology Advance Training in 2017 with dual Fellowships of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia.
He is undertaking a part-time research higher degree at Alfred Hospital/Monash University. His interests are myeloid malignancies (acute leukaemias, myelodysplastic syndromes and myeloproliferative neoplasms), but would welcome any malignant and non-malignant haematological condition. He is also active in clinical trial developments, working to translate scientific breakthroughs and seek treatment options for patients he treats.
Ing-Soo is the medical lead for Acute Lymphoblastic Leukaemia at the Austin Hospital.
Other appointments: Alfred Hospital (Clinical Haematologist), Peter MacCallum Cancer Centre (Laboratory Haematologist).
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Haematology
- Myeloid malignancies
- Acute leukaemia
- Myelodysplasia
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportice Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic (MDS)
Tiong, I. S. & Malherbe, M.
9/03/23 → 9/03/25
Project: Research
-
A Phase 1b, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Tiong, I. S. & Kennedy, N.
1/04/21 → 31/12/25
Project: Research
-
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia.
Wei, A., Tiong, I. S., Reynolds, J. & Kennedy, N.
22/09/19 → 31/12/24
Project: Research
-
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
Tiong, I. S. & Kennedy, N.
15/07/19 → 31/12/24
Project: Research
-
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Moujalled, D. M., Brown, F. C., Chua, C. C., Dengler, M. A., Pomilio, G., Anstee, N. S., Litalien, V., Thompson, E., Morley, T., MacRaild, S., Tiong, I. S., Morris, R., Dun, K., Zordan, A., Shah, J., Banquet, S., Halilovic, E., Morris, E., Herold, M. J., Lessene, G., & 5 others, 9 Feb 2023, In: Blood. 141, 6, p. 634–644 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus) -
Cellular distribution of IDH mutations in AML during morphologic remission
Ramanan, R., Tiong, I. S., Ivey, A., Ong, D. M., Brown, F. C., Chua, C., Das, T. & Curtis, D., Jan 2023, In: Leukemia Research. 124, 3 p., 106993.Research output: Contribution to journal › Article › Other › peer-review
-
ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
Wei, A. H., Iland, H. J., Reynolds, J., Loo, S., Chua, C. C., Westerman, D. A., Tiong, I. S., Ivey, A., Blombery, P., Anstee, N. S., Koldej, R., Curtis, D. J., Kipp, D. A., Ritchie, D. S., Ross, D. M., Souza, A., Collins, J., Bajel, A., Grove, C. S., Marlton, P., & 7 others, 15 Nov 2022, In: Blood. 140, Suppl 1, p. 3341-3343 3 p.Research output: Contribution to journal › Meeting Abstract › peer-review
-
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
Blombery, P., Thompson, E. R., Lew, T. E., Tiong, I. S., Bennett, R., Cheah, C. Y., Lewis, K. L., Handunnetti, S. M., Tang, C. P. S., Roberts, A., Seymour, J. F. & Tam, C. S., 25 Oct 2022, In: Blood Advances. 6, 20, p. 5589-5592 4 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Citations (Scopus) -
High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
Chua, C. C., Loo, S., Reynolds, J., Tiong, I. S., Fong, C. Y., Ting, S. B., Fleming, S., Roberts, A. W. & Wei, A. H., 1 Nov 2022, In: Blood. 140, Supplement 1, p. 1708-1710 3 p.Research output: Contribution to journal › Meeting Abstract › peer-review